2345results about How to "Improve anti-tumor effect" patented technology

The invention relates to a method for controlling the activity of an immunologically functional molecule, such as an antibody, a protein, a peptide or the like, an agent of promoting the activity of an immunologically functional molecule, and an immunologically functional molecule having the promoted activity.

Described herein are carbamate compounds. Such compounds are capable of modulating the activity of a checkpoint kinase, and described herein are methods for utilizing such modulation to treat cell proliferative disorders. Also described are pharmaceutical compositions containing such compounds. Also described are the therapeutic or prophylactic use of such compounds and compositions, and methods of treating cancer as well as other diseases associated with unwanted cellular proliferation, by administering effective amounts of such compounds in combination with anti-neoplastic agents.

The present invention relates to methods of treating mammals affected by, for example, a hyperproliferative disease such as cancer, by administering a tumor-targeted superantigen and a chemotherapeutic agent, whereby the administration of the tumor-targeted superantigen and chemotherapeutic agent reduce the antibody response and enhance the T cell response. The superantigen, wild-type or modified, is fused to a target-seeking moiety, such as an antibody or an antibody active fragment. The combined administration of a superantigen and a chemotherapeutic agent provides enhanced therapeutic effects in a treated animal.

The present invention discloses a novel chimeric antigen receptor and applications thereof, wherein the novel chimeric antigen receptor comprises a signal peptide, an antigen binding domain, a transmembrane domain and an intracellular signal domain, and comprises a 4-1BB signal peptide and/or a 4-1BB molecular transmembrane domain. According to the present invention, a variety of chimeric antigenreceptor nucleic acid sequences are separated and purified, the chimeric antigen receptor specifically for CD19 malignant tumor antigens and the CAR-T cells are provided, and the blood cell line malignant tumor killing test results show that the tumor-cell-targeting ability of immune cells is significantly enhanced, and the tumor cell killing activity is enhanced.

The present invention relates to pharmaceutical compositions comprising a sulfonamide-including compound in combination with an angiogenesis inhibitor.

As an antitumor drug which is excellent in terms of antitumor effect and safety, there is provided an antibody-drug conjugate in which an antitumor compound represented by the following formula is conjugated to an antibody via a linker having a structure represented by the following formula:

-L¹-L²-L^P-NH—(CH₂)n¹-L^a-L^b-L^c-

wherein the antibody is connected to the terminal of L¹, and the antitumor compound is connected to the terminal of L^c with the nitrogen atom of the amino group at position 1 as a connecting position.

The invention refers to a preparation method of ginseng polysaccharide. The method includes the following step: extract it from the ginseng or the marc of the ginseng decocted, filtrate, concentrate and deposit the extracting solution, get the precipitate after centrifugence and dry it with low temperature to get the crude product of ginseng polysaccharide. We get the polysaccharide product after the ginseng polysaccharide goes through the boiling, depositing, filtration, trash extraction, frost thawing, getting rid of the protein and getting the supernatant and the supernatant passes through the concentration with low pressure and drying with low temperature. We can make it into all kinds of forms of prepared drugs after the ginseng polysaccharide passes through the experiments in pharmaceutics. The invention effectively increases the quality of the ginseng polysaccharide injection, fully exerts the immunoloregulation function of the ginseng polysaccharide, increases the anti tumor effect of chemotherapy medicament and is used to reduce the side effect caused by the knubbly radiotherapy and chemotherapy as well as adjuvant for curing the tumor.

The invention discloses an AFP[158-166] specific TCR gene, its transgenic T cell, and an in-vitro proliferation method and a use of the transgenic T cell. The AFP[158-166] specificity TCR gene is represented by SEQ ID NO.1 in a sequence table. The transgenic T cell of the AFP[158-166] specific TCR gene has a specific killing effect on AFP positive liver cancer cells. Artificial antigen presentation cells can present AFP[158-166] epitope peptides through the MHCI type molecule of the cell surface when the artificial antigen presentation cells are secreted by IL-15 to induce the AFP specific immune reaction, and the stimulation of the AFP[158-166] specific TCR gene transgenic T cell by the AFP[158-166] specific TCR gene can improve the proportion of the transgenic T cell, enhances the specificity and enhances the T cell activity and the antitumor capability in an auxiliary manner through the secretion of IL-15.

The present invention relates to one kind of angiogenesis inhibiting fusion protein and its use. The fusion proteins of the present invention are produced through fusing FLT-1 segment, KDR segment and immunoglobulin Fc segment, and are named as FP1, FP2, FP3, FP4, FP5 and FP6. The amino acid sequences FLT-1 D2, FLT-1 D4, KDR, D1, KDR D3, KDR D4 and FP3 in the immunoglobulin-like area of FLT-1 and KDR are shown in the sequence lists 1-6, and FP3 coded DNA sequence is shown in the sequence list 7.

The invention belongs to the field of drug synthesis and in particular relates to a series of novel peptide boric acids as well as an ester compound or pharmaceutical salt thereof, and a preparation method and application of the peptide boric acids as well as the ester compound or pharmaceutical salt thereof in pharmacodynamics. A structure of the peptide boric acid and the ester compound or pharmaceutical salt thereof is shown in a formula I (described in the specification). The compound provided by the invention can be used for preparing a proteasome inhibitor and can further be used for treating solid tumours and blood tumours, wherein the solid tumours are selected from non-small cell lung cancer, small cell lung cancer, lung adenocarcinoma, lung squamous carcinoma, pancreatic cancer, breast cancer, prostate cancer, liver cancer, skin cancer, epithelial cell cancer, gastrointestinal stromal tumor, nasopharynx cancer and leukemia; and the blood tumours are selected from multiple myeloma, mantle cell lymphoma and histiocytic lymphoma.

An antitumor agent containing, in combination, at least one kind of antitumor agent selected from the group consisting of an antitumor agent that forms a cross-link with DNA and shows an antitumor effect, an antimetabolite antitumor agent and a taxane antitumor agent, and a histone deacetylase inhibitor. According to the present invention, an antitumor agent causing reduced side effects and having a superior antitumor activity can be provided.